Trials
17 active
35 in total · 21 in the EU
Targets
—
None known yet
What this is
- How it works
- Blocks PARP, an enzyme cancer cells use to repair their DNA, so the damaged cancer cells die.-parib: PARP inhibitors WHO name stem
- How it’s given
- “Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)”In the company’s words, NCT03602859 on ClinicalTrials.gov
- Tested for
- Ovarian Neoplasms (4 trials), Neoplasms (2 trials), Neoplasms, Breast, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma, Breast Neoplasms
- Main trialPhase 4
- “The goal of this clinical trial is to learn about the safety profile of niraparib in adult female participants for the treatment of advanced or relapsed epithelial ovarian cancer.”In the company’s words, NCT06887933 on ClinicalTrials.gov
- Other names
- ZEJULA · formerly MK-4827
Other drugs for Ovarian Neoplasms
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up2
- 26 NovPhase 3 trial completes · ClinicalTrials.gov
- 28 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials35
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | 20 Mar 2026 | A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer | |
| Phase 3Active, not recruiting | 17 May 2019 | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | |
| Phase 3Active, not recruiting | 28 Jun 2024 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease | |
| Phase 3Active, not recruiting | 31 Oct 2024 | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer | |
| Phase 3Active, not recruiting | 26 Nov 2026 | A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer | |
| Phase 2Recruiting | 28 Dec 2026 | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | |
| Phase 1/2Active, not recruiting | 30 Jun 2026 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors | |
| Phase 3Completed | 22 Apr 2016 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | |
| Phase 3Terminated | 23 May 2018 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | |
| Phase 3Completed | 26 Feb 2025 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer | |
| Phase 2Completed | 28 Feb 2018 | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | |
| Phase 2Completed | 4 May 2020 | Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | |
| Phase 2Completed | 24 Dec 2020 | A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | |
| Phase 2Terminated | 18 Aug 2021 | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer | |
| Phase 2Completed | 1 Apr 2022 | Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | |
| Phase 2Terminated | 28 Jun 2024 | A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C) | |
| Phase 2Completed | 28 Jun 2024 | A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer | |
| Phase 1/2Completed | 14 May 2018 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | |
| Phase 1Completed | 16 Sep 2019 | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients | |
| Phase 1Completed | 2 Jan 2020 | Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer | |
| Phase 1Completed | 26 Feb 2020 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | |
| Phase 1Completed | 30 Dec 2021 | Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule | |
| Phase 1Terminated | 23 Apr 2025 | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) | |
| Phase 2Authorised | not given | A Phase II randomized, open label non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy | |
| Phase 2Authorised | not given | A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery (NIRVANA-1 study) | |
| Phase 2Authorised | not given | Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway | |
| Phase 3Authorised | not given | SAFIR ABC10 : Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial | |
| Phase 2Authorised | not given | A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial) | |
| Phase 2Authorised | not given | ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling | |
| Phase 2Ended | not given | An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors (NIRADO) | |
| Phase 2Authorised | not given | A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma positive for PD-L1 expression and germline or somatic mutations in the HRR genes | |
| Phase 3Authorised | not given | Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) | |
| Phase 3Authorised | not given | Randomized phase III trial on NIraparib-Dostarlimab) vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) | |
| Phase 1/2Authorised | not given | Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head and Neck squamous cell carcinoma (RADIAN) | |
| Phase 2Ended | not given | Induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). PRIME H&N study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026